Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Rapport Therapeutics, Inc. ( (RAPP) ) has shared an announcement.
On September 8, 2025, Rapport Therapeutics, Inc. terminated its sales agreement prospectus related to its common stock, which was initially filed on July 1, 2025, with Leerink Partners LLC and Cantor Fitzgerald & Co. Despite this termination, the sales agreement itself remains effective, but no shares have been issued or sold under this agreement as of the termination date.
The most recent analyst rating on (RAPP) stock is a Buy with a $34.00 price target. To see the full list of analyst forecasts on Rapport Therapeutics, Inc. stock, see the RAPP Stock Forecast page.
Spark’s Take on RAPP Stock
According to Spark, TipRanks’ AI Analyst, RAPP is a Neutral.
Rapport Therapeutics, Inc. faces significant challenges with no revenue and substantial operational losses despite strong equity financing and low leverage. Technical indicators point to a downward trend, and valuation is difficult to ascertain. Positive clinical trial results offer some optimism, but leadership changes contribute to uncertainty.
To see Spark’s full report on RAPP stock, click here.
More about Rapport Therapeutics, Inc.
Average Trading Volume: 179,032
Technical Sentiment Signal: Buy
Current Market Cap: $524.1M
For an in-depth examination of RAPP stock, go to TipRanks’ Overview page.